RecruitingNCT06317428

NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Change in Serum Levels of NT-proBNP During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Sponsor

Istituto Nazionale di Ricovero e Cura per Anziani

Enrollment

29 participants

Start Date

Jun 28, 2022

Study Type

OBSERVATIONAL

Conditions

COPD

Summary

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study monitors heart health markers — specifically a protein called NT-proBNP in the blood — in patients with COPD (chronic obstructive pulmonary disease) who are starting a triple inhaler therapy. The combination inhaler includes formoterol, glycopyrrolate, and budesonide, which are medicines that open the airways and reduce inflammation in the lungs. Researchers want to understand how this treatment affects the heart. **You may be eligible if...** - You have been diagnosed with COPD - Your doctor has prescribed you triple inhalation therapy containing formoterol, glycopyrrolate, and budesonide **You may NOT be eligible if...** - Your life expectancy is less than one year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.